The epigenetic regulator BMI1 is upregulated progressively in a wide variety of human tumors including colorectal cancer. In this study, we assessed the requirement for Bmi1 in intestinal tumorigenesis using an autochthonous mouse model in which Apc was conditionally ablated in the intestinal epithelium. Germline mutation of Bmi1 significantly reduced both the number and size of small intestinal adenomas arising in this model, and it acted in a dose-dependent manner. Moreover, in contrast to wild-type controls, Bmi1
INTRODUCTION
Colorectal carcinoma (CRC) is the fourth leading cause of cancer deaths worldwide, resulting in over 600 000 fatalities a year. 1 Upregulation of the Wnt pathway activity, through loss of the Apc tumor suppressor or deregulation of the b-catenin protooncogene, is an early event in the development of most colon adenomas. 2 Additional mutations and epigenetic changes are associated with tumor development and progression. The oncogene BMI1 is frequently overexpressed in human CRC, and the degree of upregulation correlates with disease progression and is predictive of poor patient survival. [3] [4] [5] This suggests that BMI1 enables both the development and metastatic progression of CRC. Knockdown of Bmi1 in human CRC cell lines has been shown to suppress their proliferation in vitro and in xenografts. 6 However, the role of Bmi1 in the initiation of autochthonous intestinal tumors has not been investigated.
Much of our understanding of Bmi1's in vivo role has come from the analysis of germline Bmi1 À / À mice. 7 These animals have a shortened lifespan and they display cerebellar and hematopoietic abnormalities. These tissue defects reflect a requirement for Bmi1 to maintain the self-renewal and proliferative capacity of adult neuronal and hematopoietic stem/progenitor cells via epigenetic silencing of the Ink4a-Arf and Cdkn1a loci. [8] [9] [10] Bmi1's ability to silence these tumor suppressors and promote stem cell characteristics has been linked to Bmi1's oncogenic activity in various tumor types. 9, 11 In CRC, intestinal stem cells are thought to be the targets of transformation, 12 reflecting the importance of Wnt/b-catenin signaling in the maintenance of these cells. Bmi1 is expressed in intestinal stem cell populations, including both the þ 4 position and LGR5 þ cells, [13] [14] [15] but its requirement for their function has not been demonstrated. Here, we use mouse models to assess the requirement for Bmi1 in the development of autochthonous small intestinal tumors and show that it has a crucial role.
RESULTS AND DISCUSSION
To investigate Bmi1's role in intestinal tumorigenesis, we took advantage of an established mouse model in which a single conditional Apc fl allele 16 is inactivated throughout the intestinal epithelium using the Vil-cre transgene. 17 After somatic recombination of the wild-type Apc allele, these mice develop numerous small intestinal adenomas and a lower incidence of colon adenomas. 18 The resulting tumor load causes morbidity between 100 and 140 days of age. Importantly, this precedes the typical maximal lifespan of germline Bmi1 À / À adult mice (B150 days), allowing us to intercross these mice and assess how germline Bmi1 mutation affects the tumor phenotype of Apc; Vil-cre mice. We generated cohorts of Apc fl/ þ ;Vil-cre mice that were Bmi1
Males and females were considered separately because intestinal tumorigenesis is gender dependent. 18 Any graph showing pooled data from male and female mice (as noted in the figure legend), illustrates a phenotype that is overtly present in both sexes. Initially, we examined the tumor phenotypes of 120-day-old mice. We found that visible small intestinal tumors were numerous in Bmi1 þ / þ animals, but almost completely absent in Bmi1 À / À mice (Figures 1a and b) . Bmi1 heterozygotes displayed an intermediate phenotype, suggesting a dose-dependent effect (Figure 1b) . The analysis of all tumors (visible by eye or microscopic analysis) confirmed that Bmi1 mutation caused a significant, dose-dependent reduction in the size of small adenomas (Figure 1c) . Indeed, the median and maximal cross-sectional areas of Bmi1 À / À adenomas were more than 10-fold lower than those of Bmi1 þ / þ tumors ( Figure 1c ). In addition, even when considering lesions of any size, Bmi1 À / À mice had significantly fewer small intestinal adenomas (Po0.001) than Bmi1 þ / þ controls (Figure 1d ). Importantly, Bmi1 status did not alter the efficiency of Cre-mediated recombination (Supplementary Figure 1a) or impair key oncogenic events arising from Apc inactivation, including accumulation of nuclear b-Catenin and c-Myc (Supplementary Figure 1b) . Thus, we conclude that Bmi1 mutation acts in a dose-dependent manner to suppress small intestinal tumor development.
We also examined the effect of Bmi1 mutation on colon adenomas, and found that Bmi1 À / À animals had fewer visible tumors than Bmi1 þ / þ controls ( Supplementary Figures 2a and b) . Unfortunately, because colon tumors arise at low frequency in Apc fl/ þ ;Vil-cre mice it was difficult to establish statistical significance, and this was only achieved for male mice (Supplementary Figure 2b) . Given this challenge, we decided to focus on the small intestinal phenotype. First, we wanted to determine the effect of Bmi1 mutation at earlier stages of tumor development, and thus examined 90 day animals. At this younger age, we also observed significantly fewer (Po0.01) and smaller (Po0.01) lesions in (Figures 1d and e) . Moreover, our comparison of the 90-and 120-day time points Comparison of (d) the total number of small intestinal adenomas per histological cross-section (CS), and (e) adenoma CSA, in 90-day-old versus 120-day-old mice shows that Bmi1 is required for their maintenance and progression. Data were pooled for male and females using equal numbers of each (n ¼ 8-10 for combined genders). For (a-e) mouse small intestine was dissected, fixed in formalin, coiled and subject to histological processing followed by paraffin embedding. Sections were examined using a Nikon Eclipse E600 microscope with a SPOT RT digital camera. SPOT Basic imaging software (SPOT Imaging Solutions, Sterling Heights, MI, USA) was utilized for capture and area/length measurements. Data are presented as box plots with marked median values and whiskers spanning from the 5th to 95th percentiles. For statistical analyses (b, c) analysis of variance (ANOVA) was performed with a Tukey post-test for paired comparisons or (d, e) a student's twosided t-test was performed for paired comparisons.
showed that these two genotypes had differential effects on tumor progression (Figures 1d and e) . In Bmi1 þ / þ mice, tumor number did not change significantly between 90 and 120 days, but tumor size increased significantly (Po0.05). In contrast, Bmi1 À / À mice showed no increase in median tumor size between 90 and 120 days. Furthermore, the incidence of tumors decreased significantly (Po0.01) between these two ages. Taken together, these findings suggest that Bmi1 loss suppresses small intestinal tumor progression and maintenance.
We wanted to determine how Bmi1 loss impedes tumor progression. In many other tumor types, Bmi1's oncogenic activity is at least partially dependent upon its ability to repress the Ink4a/ Arf locus. 19 Thus, we wanted to explore the potential contribution of the p16
Ink4a and p19 Arf tumor suppressors. Although we could not perform western blot for p16
Ink4a and p19 Arf in Bmi1
À / À adenomas because of their small size, and reliable detection using immunohistochemistry in the intestine has not been demonstrated, we were able to screen wild-type and Bmi1
adenomas for these proteins. These two genotypes showed no obvious difference in p16 Ink4a levels (Supplementary Figure 3a) , but p19 Arf was typically elevated in Bmi1 þ / À tumors, compared with Bmi1 þ / þ controls (Figure 2a ). Given this, it seemed likely that p19
Arf was also upregulated in Bmi1 À / À tumors. Thus, we examined the small intestinal adenomas for the known tumor suppressive effects of p19
Arf . Initially, we assayed for senescenceassociated b-galactosidase. However, we saw no detectable differences between Bmi1 þ / þ versus Bmi1 À / À adenomas at either 90 days (little detectable senescence-associated b-galactosidase) or 120 days (low level senescence-associated b-galactosidase staining; Supplementary Figure 3b) . Next, we assessed the proliferative index of adenomas by quantification of bromodeoxyuridine incorporation at 90 days (Figure 2b) . Unexpectedly, the proportion of proliferating cells was significantly higher in Bmi1 mutant adenomas than in Bmi1 þ / þ controls, even when controlling for tumor size (Figure 2b) . Thus, neither enhanced senescence nor impaired proliferation can account for the tumor suppressive effects of Bmi1 loss. Finally, we assayed for apoptosis by quantification of cleaved caspase-3 in adenomas at 90 days (Figure 2c ). We found that this was increased significantly (Po0.01) in smaller (cross-sectional areao10 4 Arf expression in Bmi1 þ / À versus Bmi1 þ / þ adenomas. Lysates were prepared from small intestinal adenomas that were minced, digested for 1 h at 37 1C in dispase (150 u/ml final; Gibco, Carlsbad, CA, USA), triturated and lysed in radio immunoprecipitation assay buffer (200 mM Tris pH 7.4, 130 mM NaCl, 10% glycerol, 0.1% SDS, 0.5% DOC, 1% Triton) containing protease inhibitors (Roche, Indianapolis, IN, USA). Protein was separated by SDS-polyacrylamide gel electrophoresis, and western blot was performed with anti-p19
Arf (top panel; NB200-106, BD Biosciences, San Jose, CA, USA) and Histone H3 (lower panel; 4620, Cell Signaling, Danvers, MA, USA) antibodies, followed by incubation with a 1:5000 dilution of horseradish peroxidase-conjugated secondary antibodies (Cell Signaling). Relative levels of p19
Arf were quantified and normalized to the levels of Histone H3 after band density measurements using ImageJ software (NIH, RSB, Bethesda, MD, USA). Adenomas from at least five mice of each genotype consisting of both males and females were assayed. Immunohistochemistry on intestinal sections was performed after antigen retrieval in 10 mM citric acid pH 6.0 using a decloaking chamber, followed by standard DAB protocol and haematoxylin counterstain. Antibodies were: anti-BrdU (1:100; 347580, Beckton Dickson, Franklin Lakes, NJ, USA), p53 (1:500, FL-393, Santa Cruz, Santa Cruz, CA, USA) and cleaved caspase-3 (1:1000, 9661, Cell Signaling). Tissue processing, image capture/measurements and statistical analysis were performed as described for Figures 1b and c, and error bars represent s.d..
adenomas, but not in larger Bmi1
À / À tumors. We also detected cleaved caspase-3 in the non-transformed regions of Bmi1 À / À jejunum and ileum, including in Bmi1 À / À mice that lacked Vil-cre, and therefore Apc inactivation (Supplementary Figures 4a-c) . Thus, Bmi1 loss increased the predisposition of emerging intestinal adenomas, and also normal intestinal epithelium, to undergo apoptosis. p19 Arf is known to promote apoptosis through the stabilization of p53. 20 Thus, we screened for p53 levels in adenomas using immunohistochemical staining (Figure 2d) . The mean percentage of p53-positive nuclei was significantly higher in Bmi1
adenomas, had more than 25% p53-positive nuclei. Notably, we observed p53 stabilization in both smaller (cross-sectional areao10 4 mm 2 ) and larger Bmi1 À / À tumors (data not shown), even though only the small lesions had elevated apoptosis. This raised the question of whether the stabilized p53 was wild-type or mutant, particularly in the larger Bmi1 À / À tumors. To address this question, we used laser capture to isolate DNA from Bmi1 À / À and wild-type small intestinal tumors, and screened for p53 mutations by PCR, and sequencing of exons 5-9 (Supplementary Figure 5) . Unexpectedly, all of these sequences were wild-type (data not shown). Thus, we conclude that p53 is activated in a high fraction of Bmi1 À / À adenoma cells, but elevated apoptosis is somehow limited to the smaller tumors.
We wanted to assess the degree to which p19 Arf contributes to the phenotypes of Bmi1 mutant tumors. Thus, we crossed an Arf null strain 21 into our mouse model to generate Apc fl/ þ ;Vil-cre mice that were wild-type, Arf
As the introduction of mutant Arf caused some animals to develop tumorassociated morbidity (cachexia and hunching) by 90 days, we selected this age for analysis (Figure 3) . Previous studies showed that Ink4a/Arf À / À mice have a lower small intestinal tumor burden than wild-type controls. 22 Consistent with this report, we found that Arf À / À mice had a similar tumor incidence as wild-type controls, (Figures 3a and b) but the median size of these Arf À / À tumors was significantly reduced (Po0.01; Figures 3a and c) . In stark contrast, þ / þ tumors while promoting Bmi1 À / À tumors. Tissue processing and image capture/measurements were performed as described for Figure 1 . For statistical analysis, ANOVA was performed, followed by an unpaired Fisher's least significant difference test for paired comparisons.
Bmi1
À / À ;Arf À / À mice had a significant increase in both the number (Po0.01; Figures 3a and b) and size (Po0.001; Figures 3a and c) of small intestinal adenomas compared with Bmi1 À / À animals. Indeed, the tumor phenotypes of these Bmi1 À / À ;Arf
animals now approached that of the Arf À / À animals ( Figure 3) ; there was no significance difference in total tumor number (Figure 3b ) or tumor size (Figure 3c ) between these two genotypes, but Bmi1 À / À ;Arf À / À mice did have significantly fewer visible lesions than Arf À / À animals (Po0.01, data not shown) suggesting that the rescue is not complete. Because we cannot follow the cohort beyond 90 days, we were unable to determine whether Arf loss altered the influence of Bmi1 deficiency on the progression and/or maintenance of tumors between 90 and 120 days. Importantly, the analysis of the 90 day tumors showed that Arf loss significantly suppressed the elevation of cleaved caspase-3 (Po0.05, Figure 2c) , and the stabilization of p53 (Figure 2d) ; Po0.01, within the Bmi1 À / À adenomas. Thus, we conclude that Arf has a major role in the ability of Bmi1 deficiency to suppress small intestinal tumors through the activation of p53 and induction of apoptosis.
We had previously noted that Bmi1 deficiency also causes apoptosis within the normal intestinal epithelium (Supplementary Figure 4) . Unexpectedly, our analysis of the Bmi1 À / À ;Arf À / À compound mutant mice showed that Arf inactivation had no significant impact on this normal tissue apoptosis. Thus, Bmi1 loss promotes apoptosis through distinct mechanisms in normal, versus transformed, intestinal epithelium. We wished to establish whether the Bmi1 mutant tumor suppression was intrinsic to the intestinal epithelium. To address this, we engineered a conditional Bmi1 (Bmi1 fl ) mutant mouse strain that allowed Cre-dependent deletion of Bmi1 core functions (encoded by exons [4] [5] [6] [7] [8] , and confirmed that this conditional Bmi1 mutant allele recapitulates all of the developmental defects characteristic of germline Bmi1 mutants (Supplementary Figure 6) . À / À ;Apc fl/ þ ;Vil-cre mice. Initially, we examined animals at 120 days. We found that the intestine-specific Bmi1 deletion significantly reduced the number of visible lesions (Po0.0001, Figures 4a and b) , the number of total lesions (Po0.001, Figure 4c ) and the size of lesions (Po0.05, Figure 4d ) in the small intestine. Importantly, the conditional Bmi1 mutant phenotypes were all indistinguishable from those yielded by germline Bmi1 deletion (Figures 4a-d) . We also examined the tumor phenotypes in 90-day-old mice to address the issue of progression and maintenance. At this time point, the intestinalspecific deletion of Bmi1 also resulted in significantly fewer (Po0.05) and smaller (Po0.01) lesions than the Bmi1 þ / þ controls (data not shown). Moreover, exactly as seen in the germline þ ;Vil-cre mice had significantly more adenomas at 90 versus 120 days (Po0.01, Figure 4e ), and there was no increase in tumor size between these two time points (Figure 4f) . Thus, the ability of Bmi1 deficiency to suppress the progression, and maintenance, of small intestinal tumors reflects an intrinsic defect of the transformed epithelium. To complement this, we also examined the level of apoptosis and the induction of p53 within the small intestinal adenomas. As anticipated, given the observed tumor suppression, conditional Bmi1 deletion promoted both the stabilization of p53 and elevated levels of apoptosis in a similar manner to germline Bmi1 loss (data not show). Finally, we screened for apoptosis in the normal epithelium. In this setting, the intestinal-specific deletion of Bmi1 gave no induction of cleaved caspase-3 (data not shown) in stark contrast to the significantly increased cleaved caspase-3 levels resulting from germline Bmi1 mutation (Po0.01, Supplementary  Figure 4 ). This further distinguishes the normal epithelial apoptosis from that of the adenomas, by showing that it is both Arf independent and non-cell autonomous. We initiated this study because of the known presence of highBmi1 expression in human CRC. 4, 5 Our goal was to assess the requirement for Bmi1 in the context of autochthonous intestinal tumors. Our data clearly show that Bmi1 loss reduces both the number and size of small intestinal adenomas. In addition, as Bmi1 animals age, we actually see a reduction in the tumor burden that reflects an apparent cap on tumor size, and a clear reduction in the total number of tumors. Thus, taken together, these data support a key role for Bmi1 in tumor development, progression and maintenance. This tumor suppression correlates with the upregulation of Arf, stabilization of p53 and a significant increase in the level of apoptosis in smaller adenomas. Our analysis of Arf null mice showed that these molecular changes are linked, and that they make a major contribution to the antitumorigenic effect of Bmi1 loss in small intestinal adenomas. Finally, our data show that the Arf-dependent induction of apoptosis, and the consequent tumor suppression, reflects a cell autonomous requirement for Bmi1 within the intestinal epithelium.
